Drug distributor McKesson seen getting likely boost from COVID vaccine demand
McKesson Corp is expected to report strong earnings on Wednesday as an Omicron-driven surge in demand for COVID-19 vaccines and tests is likely to insulate the drug distributor from tepid sales of other medical products. The unit which sells medical and surgical products contributes about 5% to McKesson's revenue, compared with rival Cardinal Health Inc's similar business accounting for 10%. A surge in COVID-19 cases due to the fast-spreading Omicron variant has overwhelmed hospitals, forcing them to turn away patients seeking less-urgent procedures.
Reuters - February 3, 2022View the full story here: https://www.reuters.com/business/healthcare-pharmaceuticals/drug-distributor-mckesson-seen-getting-likely-boost-covid-vaccine-demand-2022-02-02/